Difference between revisions of "Part:BBa K404122:Design"

Revision as of 20:36, 27 October 2010

[AAV2]-left-ITR_pCMV_betaglobin_mGMK_TK30_hGH_[AAV2]-right-ITR

Assembly Compatibility:

10
COMPATIBLE WITH RFC[10]
12
COMPATIBLE WITH RFC[12]
21
COMPATIBLE WITH RFC[21]
23
COMPATIBLE WITH RFC[23]
25
INCOMPATIBLE WITH RFC[25]
Illegal NgoMIV site found at 1319
Illegal NgoMIV site found at 1977
Illegal NgoMIV site found at 2882
Illegal AgeI site found at 3011
1000
INCOMPATIBLE WITH RFC[1000]
Illegal BsaI site found at 3413
Illegal SapI.rc site found at 1369

Design Notes

x

Source

x

References

References. 16

References

Ardiani, A., Sanchez-Bonilla, M. & Black, M.E., 2010. Fusion enzymes containing HSV-1 thymidine kinase mutants and guanylate kinase enhance prodrug sensitivity in vitro and in vivo. Cancer gene therapy, 17(2), 86-96. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2808426&tool=pmcentrez&rendertype=abstract.

Black, M.E. et al., 1996. Creation of drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene therapy. Proceedings of the National Academy of Sciences of the United States of America, 93(8), 3525-9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=39643&tool=pmcentrez&rendertype=abstract.

Fuchita, M. et al., 2009. Bacterial cytosine deaminase mutants created by molecular engineering show improved 5-fluorocytosine-mediated cell killing in vitro and in vivo. Cancer research, 69(11), 4791-9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2765227&tool=pmcentrez&rendertype=abstract.

Greco, O. & Dachs, G.U., 2001. Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. Journal of cellular physiology, 187(1), 22-36. Available at: http://www.ncbi.nlm.nih.gov/pubmed/11241346.

Huber, B.E. et al., 1993. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer research, 53(19), 4619-26. Available at: http://www.ncbi.nlm.nih.gov/pubmed/8402637.

Huber, B.E. et al., 1994. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proceedings of the National Academy of Sciences of the United States of America, 91(17), 8302-6. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44594&tool=pmcentrez&rendertype=abstract.

Moolten, F.L., 1986. Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer research, 46(10), 5276-81. Available at: http://www.ncbi.nlm.nih.gov/pubmed/3019523.

Roche, Apoptosis , Cell Death and Cell Proliferation,

Willmon, C.L., Krabbenhoft, E. & Black, M.E., 2006. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing. Gene therapy, 13(17), 1309-12. Available at: http://www.ncbi.nlm.nih.gov/pubmed/16810197.

@@ Line 1: / Line 1: @@
 __NOTOC__
 <partinfo>BBa_K404122 short</partinfo>
@@ Line 16: / Line 15: @@
 ===References===
+<html>
+<p class=MsoToc3><span class=MsoHyperlink><a href="#_Toc275981849"><span
+lang=EN-US>References</span><span style='color:windowtext;display:none;
+text-decoration:none'>. </span><span
+style='color:windowtext;display:none;text-decoration:none'>16</span></a></span></p>
+<h3><a name="_Toc275981849"><span lang=EN-US>References</span></a></h3>
+<p style='text-indent:36.0pt'><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Ardiani, A., Sanchez-Bonilla, M. &amp;
+Black, M.E., 2010. Fusion enzymes containing HSV-1 thymidine kinase mutants and
+guanylate kinase enhance prodrug sensitivity in vitro and in vivo. <i>Cancer
+gene therapy</i>, 17(2), 86-96. Available at:
+http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2808426&amp;tool=pmcentrez&amp;rendertype=abstract.</span></p>
+<p style='text-indent:36.0pt'><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Black, M.E. et al., 1996. Creation of
+drug-specific herpes simplex virus type 1 thymidine kinase mutants for gene
+therapy. <i>Proceedings of the National Academy of Sciences of the United
+States of America</i>, 93(8), 3525-9. Available at:
+http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=39643&amp;tool=pmcentrez&amp;rendertype=abstract.</span></p>
+<p style='text-indent:36.0pt'><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Fuchita, M. et al., 2009. Bacterial
+cytosine deaminase mutants created by molecular engineering show improved
+-fluorocytosine-mediated cell killing in vitro and in vivo. <i>Cancer research</i>,
+(11), 4791-9. Available at:
+http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2765227&amp;tool=pmcentrez&amp;rendertype=abstract.</span></p>
+<p style='text-indent:36.0pt'><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Fuchita, M. et al., 2009. Bacterial
+cytosine deaminase mutants created by molecular engineering show improved
+-fluorocytosine-mediated cell killing in vitro and in vivo. <i>Cancer research</i>,
+(11), 4791-9. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=2765227&amp;tool=pmcentrez&amp;rendertype=abstract.</span></p>
+<p style='text-indent:36.0pt'><span style='font-size:10.0pt;font-family:"Calibri","sans-serif"'>Greco,
+O. &amp; Dachs, G.U., 2001. </span><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Gene directed enzyme/prodrug therapy of
+cancer: historical appraisal and future prospectives. <i>Journal of cellular
+physiology</i>, 187(1), 22-36. Available at:
+http://www.ncbi.nlm.nih.gov/pubmed/11241346.</span></p>
+<p style='text-indent:36.0pt'><span style='font-size:10.0pt;font-family:"Calibri","sans-serif"'>Huber,
+B.E. et al., 1993. </span><span lang=EN-US style='font-size:10.0pt;font-family:
+"Calibri","sans-serif"'>In vivo antitumor activity of 5-fluorocytosine on human
+colorectal carcinoma cells genetically modified to express cytosine deaminase. <i>Cancer
+research</i>, 53(19), 4619-26. Available at:
+http://www.ncbi.nlm.nih.gov/pubmed/8402637.</span></p>
+<p style='text-indent:36.0pt'><span style='font-size:10.0pt;font-family:"Calibri","sans-serif"'>Huber,
+B.E. et al., 1994. </span><span lang=EN-US style='font-size:10.0pt;font-family:
+"Calibri","sans-serif"'>Metabolism of 5-fluorocytosine to 5-fluorouracil in
+human colorectal tumor cells transduced with the cytosine deaminase gene:
+significant antitumor effects when only a small percentage of tumor cells
+express cytosine deaminase. <i>Proceedings of the National Academy of Sciences
+of the United States of America</i>, 91(17), 8302-6. Available at:
+http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=44594&amp;tool=pmcentrez&amp;rendertype=abstract.</span></p>
+<p style='text-indent:36.0pt'><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Moolten, F.L., 1986. Tumor chemosensitivity
+conferred by inserted herpes thymidine kinase genes: paradigm for a prospective
+cancer control strategy. <i>Cancer research</i>, 46(10), 5276-81. Available at:
+http://www.ncbi.nlm.nih.gov/pubmed/3019523.</span></p>
+<p style='text-indent:36.0pt'><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Roche, <i>Apoptosis , Cell Death and Cell
+Proliferation</i>,</span></p>
+<p style='text-indent:36.0pt'><span lang=EN-US style='font-size:10.0pt;
+font-family:"Calibri","sans-serif"'>Willmon, C.L., Krabbenhoft, E. &amp; Black,
+M.E., 2006. A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances
+prodrug-mediated cell killing. <i>Gene therapy</i>, 13(17), 1309-12. Available
+at: http://www.ncbi.nlm.nih.gov/pubmed/16810197.</span></p>
+</html>